MLICM
PDLI

Metropolitan Life Insurance Company (MetLife)’s PDL BioPharma, Inc. PDLI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,651
Closed -$58.8K – 2618
2020
Q3 		$58.8K Sell
18,651
-18,843
-50% -$60.2K ﹤0.01% 2448
2020
Q2 		$109K Buy
37,494
+58
+0.2% +$183 ﹤0.01% 2204
2020
Q1 		$106K Sell
37,436
-1,802
-5% -$5.81K ﹤0.01% 1999
2019
Q4 		$127K Buy
39,238
+17,396
+80% +$50.5K ﹤0.01% 2184
2019
Q3 		$47.2K Sell
21,842
-24,620
-53% -$65.8K ﹤0.01% 2503
2019
Q2 		$146K Hold
46,462
– – ﹤0.01% 2105
2019
Q1 		$173K Sell
46,462
-612
-1% -$2.07K ﹤0.01% 1999
2018
Q4 		$137K Hold
47,074
– – ﹤0.01% 2076
2018
Q3 		$124K Hold
47,074
– – ﹤0.01% 2331
2018
Q2 		$110K Hold
47,074
– – ﹤0.01% 2265
2018
Q1 		$138K Buy
47,074
+5,386
+13% +$14.7K ﹤0.01% 2118
2017
Q4 		$114K Sell
41,688
-73,156
-64% -$225K ﹤0.01% 2235
2017
Q3 		$389K Sell
114,844
-1,533
-1% -$4.26K ﹤0.01% 1850
2017
Q2 		$287K Buy
116,377
+6,286
+6% +$14.5K ﹤0.01% 2106
2017
Q1 		$250K Sell
110,091
-7,985
-7% -$17.7K ﹤0.01% 2126
2016
Q4 		$250K Buy
118,076
+1,239
+1% +$3.46K ﹤0.01% 2206
2016
Q3 		$391K Buy
116,837
+1,375
+1% +$4.37K ﹤0.01% 1862
2016
Q2 		$363K Hold
115,462
– – ﹤0.01% 1893
2016
Q1 		$384K Hold
115,462
– – ﹤0.01% 1748
2015
Q4 		$409K Hold
115,462
– – ﹤0.01% 1752
2015
Q3 		$581K Buy
115,462
+16,005
+16% +$91.7K ﹤0.01% 1537
2015
Q2 		$640K Sell
99,457
-27,560
-22% -$185K ﹤0.01% 1585
2015
Q1 		$894K Sell
127,017
-452
-0.4% -$3.27K 0.01% 1257
2014
Q4 		$983K Hold
127,469
– – 0.01% 1325
2014
Q3 		$952K Sell
127,469
-4,448
-3% -$41.3K 0.01% 1306
2014
Q2 		$1.28M Buy
131,917
+4,919
+4% +$43.8K 0.01% 1212
2014
Q1 		$1.05M Buy
126,998
+7,831
+7% +$67.1K 0.01% 1308
2013
Q4 		$1.01M Hold
119,167
– – 0.01% 1328
2013
Q3 		$950K Hold
119,167
– – 0.01% 1311
2013
Q2 		$920K Buy
+119,167
New +$929K 0.01% 1287

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.4% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PDLI Position: Q4 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 18,651 shares — an estimated $58.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $1.28M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 18,651 PDL BioPharma, Inc. shares in Q4 2020, an estimated $58.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s PDL BioPharma, Inc. position peaked at $1.28M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.